Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Martin, M, Holmes, FA, Ejlertsen, B et al. (32 more authors) (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 18 (12). pp. 1688-1700. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Martin, M
  • Holmes, FA
  • Ejlertsen, B
  • Delaloge, S
  • Moy, B
  • Iwata, H
  • von Minckwitz, G
  • Chia, SKL
  • Mansi, J
  • Barrios, CH
  • Gnant, M
  • Tomašević, Z
  • Denduluri, N
  • Šeparović, R
  • Gokmen, E
  • Bashford, A
  • Ruiz Borrego, M
  • Kim, S-B
  • Jakobsen, EH
  • Ciceniene, A
  • Inoue, K
  • Overkamp, F
  • Heijns, JB
  • Armstrong, AC
  • Link, JS
  • Joy, AA
  • Bryce, R
  • Wong, A
  • Moran, S
  • Yao, B
  • Xu, F
  • Auerbach, A
  • Buyse, M
  • Chan, A
  • for the ExteNET Study Group,
Dates:
  • Published: December 2017
  • Published (online): 13 November 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 11 Oct 2018 15:12
Last Modified: 18 Oct 2018 10:14
Status: Published
Publisher: Elsevier (The Lancet)
Identification Number: https://doi.org/10.1016/S1470-2045(17)30717-9

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics